美国食品和药物管理局批准使用双IL-17A/F抑制剂BIMZELX治疗多种炎症性疾病. FDA approves BIMZELX, a dual IL-17A/F inhibitor, for treating multiple inflammatory diseases.

FDA 已批准 BIMZELX （bimekizumab-bkzx） 用于治疗成人活动性银屑病关节炎、伴有炎症的非放射学中轴型脊柱关节炎和强直性脊柱炎。 The FDA has approved BIMZELX (bimekizumab-bkzx) for treating active psoriatic arthritis, non-radiographic axial spondyloarthritis with inflammation, and ankylosing spondylitis in adults. 这是美国批准用于这些疾病的第一种IL-17A和IL-17F抑制剂,突出了对慢性炎症患者的潜在好处。 It is the first IL-17A and IL-17F inhibitor authorized in the U.S. for these conditions, highlighting its potential benefits for patients with chronic inflammatory diseases. 制造商UCB强调双重抑制在改善治疗结果方面的优势。 UCB, the manufacturer, emphasizes the advantages of dual inhibition in improving treatment outcomes.